Transmembrane-4 L-six family member-1 (TM4SF1) promotes non-small cell lung cancer proliferation, invasion and chemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis

Abstract

Background Tumor chemo-resistance is a hallmark of malignant tumors as well as the major cause of poor survival rates in lung cancer. Transmembrane-4 L-six family member-1 (TM4SF1) , an antigen that serves as an oncogene, mainly affects tumor invasion and metastasis. We investigated the roles of TM4SF1 in non-small-cell lung cancer progression, particularly in the regulation of chemo-sensitivity. Methods TM4SF1 was silenced by small interfering RNA transfection. TM4SF1 expression in cell lines and tissues were determined by Quantitative Real-time PCR. MTS, clonogenic, Transwell assay, Flow cytometry verified cell function. By RT-PCR, Western blot, the mechanisms were studied. Results TM4SF1 was upregulated in both lung cancer cell lines and tissues, compared with 293 T epithelial cells. Analysis of online databases revealed that high expression of TM4SF1 is associated with the older patient age, smoking habits, and poor patient survival and outcome. Knockdown of TM4SF1 substantially inhibited tumor cell growth, migration, and invasion, and enhanced the chemo-sensitivity of the lung cancer cell lines A549 and H1299 to cisplatin and paclitaxel. Furthermore, the silencing of TM4SF1 induced lung cancer cell apoptosis and arrested cells at the G2/M phase. These results suggest that TM4SF1 is associated with lung cancer progression and appears to be required for tumor cell growth, maintenance of chemo-resistance and metastasis. We further found that TM4SF1 exerts these effects in part by regulating the expression of the discoidin domain receptor DDR1 and its downstream target, the Akt/ERK/mTOR pathway, and consequently alters cell sensitivity to chemo-reagents and contributes to invasion and metastasis. Conclusions These findings demonstrate that TM4SF1 may serve as a prognostic factor for lung cancer chemo-response and patient outcome.

Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

“…The similar poor prognosis has also been confirmed in HNSCC [53]. Mechanically, Ye et al [54] recently found that smoking increased the expression of the TM4SF1 gene, which promotes NSCLC proliferation, invasion, and chemo-resistance through regulation of the DDR1/Akt/ERK-mTOR axis. Therefore, poor prognosis in control arms may play a lateral role in highlighting the efficacy of anti-PD-1/PD-L1 therapy.…”

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges

“…These results suggest that ARK can enhance DNA damage repair by activating CHK1, which ultimately invalidates the Wee1 inhibitor. Similarly, Ye et al [41] demonstrated that in non-small cell lung cancer (NSCLC), transmembrane-4 L-six family member-1 (TM4SF1) regulates tumor sensitivity to chemotherapy drugs by regulating the expression of discoid domain receptor 1 (DDR1)/Akt/ERK/mTOR pathway.…”

RNA sequencing‑based identification of potential targets in acute myeloid leukemia: A case report

“…Finally, the present study identified TM4SF1 as a potential crucial hit in AML. TM4SF1 is a transmembrane protein with oncogenic properties in lung cancer, where it has been shown to participate in cell migration and tumor metastasis (39). In addition, TM4SF1 was also reported to promote metastasis in pancreatic cancer (40).…”